Revenue beat, but the earnings result was not clean. Total second-quarter revenue reached $243.7 million versus a published consensus of roughly $223 million, while EPS was a $0.78 loss versus consensus near a $0.63 loss. Attruby supplied $222.4 million of product revenue, up 211% year over year, while royalty revenue rose to $15.4 million; the comparison benefited partly from $30.0 million of license and milestone revenue recognized in the prior-year quarter. (Financial Highlights)
| Metric | Q2 2026 | Q2 2025 | Read-through |
|---|---|---|---|
| Total revenue | $243.7M | $110.6M | Up 120%; above published consensus of ~$223M |
| Attruby net product revenue | $222.4M | $71.5M | Up 211%; primary growth driver |
| Operating loss | $(107.1)M | $(134.3)M | Improved despite heavier launch spending |
| Net loss attributable to common stockholders | $(152.2)M | $(181.9)M | Improved year over year |
| EPS | $(0.78) | $(0.95) | Worse than published consensus near $(0.63) |
| Cash, cash equivalents and marketable securities | $720.2M | $587.5M at Dec. 31, 2025 | Higher, but operating cash burn remained substantial |
Attruby execution was the strongest part of the quarter. The product’s first-line share continued to rise, and the filing highlighted new kidney-related analyses, additional heart-failure data, and real-world comparisons against tafamidis. These data may strengthen the commercial positioning, but they are post-hoc or observational rather than new randomized evidence, so the filing adds support to the existing thesis more than it fundamentally changes the clinical proof standard. (Attruby Commercial Update; Clinical Data)
The pipeline moved from development toward regulatory decisions. BBP-418 and encaleret both have FDA Priority Review and set PDUFA dates of November 27, 2026 and May 8, 2027, respectively; the company also submitted the achondroplasia NDA for oral infigratinib. This reduces development uncertainty and makes the next value inflection points more concrete, although approval and launch outcomes remain ahead rather than delivered in this quarter. (Program Status and Milestones; Pipeline Updates)
The cost structure is scaling faster alongside commercialization. SG&A increased 44% and R&D increased 34% year over year as BridgeBio funded Attruby commercialization and preparation for three potential launches. That spending helped produce a smaller operating loss, but it also contributed to the EPS shortfall relative to expectations. (Operating Costs and Expenses; Income Statement)
Net read: commercially encouraging, financially mixed. The revenue beat and regulatory progress were better than the standing expectation, but the larger-than-expected per-share loss and continued $268.4 million of operating cash use prevent this from reading as a straightforward positive quarter. The filing strengthens the commercial and pipeline narrative while leaving investors to watch whether Attruby growth can outpace the company’s expanding launch infrastructure and financing burden. (Cash Flow Statement; Balance Sheet)
Read the original 8-K on SEC EDGAR ↗